GLP-1 makers face vision-loss lawsuits as obesity-drug race shifts beyond weekly injections
AI Summary- Patients filed U.S. lawsuits alleging GLP-1 drugs caused NAION-related vision loss.
- More than 90 New Jersey suits have been filed since 2025 by Weitz & Luxenberg.
- Drugmakers are developing oral, monthly, quarterly and other long-acting obesity treatments.